Molecular features of human pathological Tau distinguish tauopathy-associated dementias (primary cohort FLEXITau)
Ontology highlight
ABSTRACT: In Alzheimer’s disease (AD), pathological Tau protein shows a progressive accumulation of post-translational modifications (PTMs), reflecting disease severity, progression, and prion-like activity. While many neurodegenerative diseases with dementia display Tau aggregates, the pathological proteoforms of Tau protein from each disease type remain unknown. Here, using quantitative mass spectrometry-based proteomics methods, deep characterization of pathological Tau protein isolated from the brains of 203 human subjects with AD, familial AD (fAD), chronic traumatic encephalopathy (CTE), corticobasal degeneration (CBD), Pick’s disease (PiD), progressive supranuclear palsy (PSP), dementia with Lewy bodies - symptomatic control (DLB), and healthy controls (CTRL) is performed. Unsupervised data analyses and supervised machine learning identify distinct molecular features of pathological Tau for each disease, enabling molecular disease stratification. This study identifies potential disease-specific biomarkers and therapeutic targets for tauopathies and provides critical pharmacokinetics data for therapeutic and disease mechanism studies.
INSTRUMENT(S):
ORGANISM(S): Homo Sapiens (human)
TISSUE(S): Brain
DISEASE(S): Lewy Body Dementia,Chronic Traumatic Encephalopathy,Progressive Supranuclear Palsy,Alzheimer's Disease,Corticobasal Degeneration Syndrome,Pick's Disease
SUBMITTER:
Christoph Schlaffner
LAB HEAD: Judith A. Steen
PROVIDER: PXD069437 | Pride | 2026-02-19
REPOSITORIES: Pride
ACCESS DATA